CD8A and leukemia: Lenalidomide treatment significantly increased the cytotoxic activity of NK cells (1.5-fold induction) and NKT-like cells (2-fold induction) against primary leukemia cells (Figures 7(a) and 7(b)), but no effect was observed on CD8 T cells (shown in Figure 7(a)).